Zelluna
Zelluna ASA is a Norwegian clinical-stage biopharmaceutical and immunotherapy enterprise specializing in the discovery, development, and commercialization of engineered T-cell receptor (TCR) therapies designed to treat solid tumor cancers. The company utilizes proprietary non-engineered and engineered TCR technology platforms to develop cellular immunotherapies that direct patient immune cells to recognize and destroy hard-to-treat cancerous tumors. Its core business operations encompass biopharmaceutical research, cellular immunotherapy engineering, clinical trial execution, and pharmaceutical product development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings, grants, and strategic research partnerships. Zelluna holds a pioneering market position in T-cell receptor immunotherapy and solid tumor oncology. The company is headquartered in Oslo, Norway, and operates as a specialized biotechnology enterprise.
3 of the funds FundTelligence covers report a position in Zelluna.
- Legal name
- Zelluna ASA
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 3
Funds holding Zelluna
- Nordea Norge Pluss — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)
- Nordea Avkastning — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)
- Storebrand Indeks Norge — Storebrand · 0.0 % (full portfolio disclosed, October 2026)